Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fluorine 18 MK 6240 - Cerveau/Merck

Drug Profile

Fluorine 18 MK 6240 - Cerveau/Merck

Alternative Names: [18F]MK 6240; [18F]MNI-946; [F-18]MK-6240; Fluorine-18-MK6240; MK-6240

Latest Information Update: 27 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Merck Sharp & Dohme
  • Developer Cerveau Technologies; Janssen Pharmaceuticals; Merck Sharp & Dohme; Washington University School of Medicine
  • Class Amines; Diagnostic agents; Imaging agents; Isoquinolines; Pyridines; Pyrroles; Radiopharmaceutical diagnostics
  • Mechanism of Action Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II/III Alzheimer's disease
  • Phase II Neurodegenerative disorders

Most Recent Events

  • 25 Nov 2019 Phase-I clinical trials in Alzheimer's disease (Diagnosis) in Japan (IV)
  • 01 Nov 2019 The Pharmaceutical and Medical Devices Agency approves clinical study for Fluorine 18 MK 6240 in Alzheimer’s disease, before November 2019
  • 30 Sep 2019 Cerveau Technologies enters into a agreement with Takeda for Flurine 18 MK 6240 in diagnosis of neurofibrillary tangles
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top